FLOW Trial Results: Semaglutide for Kidney Disease
FLOW trial results explained — how semaglutide demonstrated kidney protective effects and what this means for patients with obesity and chronic kidney disease.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. Updated when new research or guidelines are published.
Quick links: Semaglutide treatment, tirzepatide treatment, and best GLP-1 provider guide.
More on GLP-1 Clinical Evidence
Frequently Asked Questions
What does this research mean for GLP-1 patients?
This research adds to the growing body of evidence supporting GLP-1 medications as effective, evidence-based treatments for obesity and related metabolic conditions. For patients considering treatment, understanding the clinical evidence helps set realistic expectations and make informed decisions. Providers like Trimi use this evidence base to guide personalized treatment plans.
How reliable is the evidence discussed in this article?
The studies and guidelines referenced in this article come from peer-reviewed medical journals, government health agencies, and established medical organizations. These represent the highest levels of clinical evidence available. We cite primary sources so readers can verify the information independently.
Does this evidence apply to compounded GLP-1 medications?
Clinical trials typically use brand-name medications. Compounded versions contain the same active ingredients and are expected to produce similar results when properly formulated by accredited pharmacies. While compounded versions have not been independently studied in large trials, the pharmacological basis is the same.
How can I use this information when choosing a provider?
Understanding the clinical evidence helps you evaluate provider claims and set realistic expectations. Look for providers whose treatment protocols align with published evidence, who can discuss the research behind their prescribing decisions, and who offer transparent information about their medications and processes.
Where can I find more GLP-1 research information?
PubMed, the New England Journal of Medicine, The Lancet, and the FDA website are authoritative sources for GLP-1 clinical data. Our education hub covers the major studies and guidelines in patient-friendly language. Trimi providers can also discuss the evidence base during your consultations.
Is GLP-1 treatment right for me based on this evidence?
Clinical eligibility for GLP-1 treatment generally requires a BMI of 30 or higher, or 27 or higher with weight-related comorbidities. The evidence strongly supports GLP-1 medications for patients meeting these criteria. A qualified provider can evaluate your specific situation — Trimi offers consultations with metabolic health specialists at no additional cost.
How do I get started with evidence-based GLP-1 treatment?
Trimi offers compounded semaglutide and tirzepatide starting at $149 per month through providers who specialize in metabolic health. Complete a health questionnaire, get evaluated by a specialist, and receive your medication in 5-7 days. No insurance required, no contracts, no hidden fees.
Sources & References
- Wilding JPH, et al. STEP 1 trial. N Engl J Med. 2021.
- Jastreboff AM, et al. SURMOUNT-1 trial. N Engl J Med. 2022.
- Lincoff AM, et al. SELECT trial. N Engl J Med. 2023.
- FDA compounding regulation.
- Wegovy prescribing information.
- Zepbound prescribing information.
- NIDDK prescription weight loss medications.
- CDC obesity facts and statistics.
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication. Trimi offers GLP-1 treatment — readers should be aware of our perspective.